{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:04:04Z","timestamp":1792101844015,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40257-023-00796-2","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T04:02:27Z","timestamp":1687924947000},"page":"977-990","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Disease Burden and Treatment Patterns Among US Patients with Hidradenitis Suppurativa: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-6856","authenticated-orcid":false,"given":"Amit","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Geissb\u00fchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Houchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Vellanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Priyanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"John","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9405-0479","authenticated-orcid":false,"given":"Alexa B.","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,28]]},"reference":[{"issue":"1","key":"796_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/BCR.0b013e31826a7be7","volume":"34","author":"TA Gonzaga","year":"2013","unstructured":"Gonzaga TA, Endorf FW, Mohr WJ, Ahrenholz DH. Novel surgical approach for axillary hidradenitis suppurativa using a bilayer dermal regeneration template: a retrospective case study. J Burn Care Res. 2013;34(1):51\u20137.","journal-title":"J Burn Care Res"},{"issue":"2","key":"796_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","volume":"366","author":"GB Jemec","year":"2012","unstructured":"Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158\u201364.","journal-title":"N Engl J Med"},{"issue":"1","key":"796_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, Jemec GBE, Matusiak L, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"796_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200683","volume":"13","author":"M Calao","year":"2018","unstructured":"Calao M, Wilson JL, Spelman L, Billot L, Rubel D, Watts AD, et al. Hidradenitis suppurativa (HS) prevalence, demographics and management pathways in Australia: a population-based cross-sectional study. PLoS ONE. 2018;13(7): e0200683.","journal-title":"PLoS ONE"},{"issue":"3","key":"796_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/jdv.14686","volume":"32","author":"E Delany","year":"2018","unstructured":"Delany E, Gormley G, Hughes R, McCarthy S, Kirthi S, Markham T, et al. A cross-sectional epidemiological study of hidradenitis suppurativa in an Irish population (SHIP). J Eur Acad Dermatol Venereol. 2018;32(3):467\u201373.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"796_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jaad.2017.02.005","volume":"77","author":"A Garg","year":"2017","unstructured":"Garg A, Lavian J, Lin G, Strunk A, Alloo A. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2017;77(1):118\u201322.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"796_CR7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/bjd.16101","volume":"178","author":"JR Ingram","year":"2018","unstructured":"Ingram JR, Jenkins-Jones S, Knipe DW, Morgan CLI, Cannings-John R, Piguet V. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018;178(4):917\u201324.","journal-title":"Br J Dermatol"},{"key":"796_CR8","doi-asserted-by":"publisher","unstructured":"Phan K, Charlton O, Smith SD. Global prevalence of hidradenitis suppurativa and geographical variation\u2014systematic review and meta-analysis. Biomed Dermatol. 2020;4:2. https:\/\/doi.org\/10.1186\/s41702-019-0052-0.","DOI":"10.1186\/s41702-019-0052-0"},{"issue":"5","key":"796_CR9","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jaad.2013.06.043","volume":"69","author":"S Sung","year":"2013","unstructured":"Sung S, Kimball AB. Counterpoint: analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;69(5):818\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"796_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/jid.2012.255","volume":"133","author":"BG Vazquez","year":"2013","unstructured":"Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133(1):97\u2013103.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"796_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334.","journal-title":"N Engl J Med"},{"issue":"12","key":"796_CR12","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s40265-021-01566-2","volume":"81","author":"P Aarts","year":"2021","unstructured":"Aarts P, Dudink K, Vossen A, van Straalen KR, Ardon CB, Prens EP, et al. Clinical implementation of biologics and small molecules in the treatment of hidradenitis suppurativa. Drugs. 2021;81(12):1397\u2013410.","journal-title":"Drugs"},{"issue":"5","key":"796_CR13","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","volume":"86","author":"A Garg","year":"2022","unstructured":"Garg A, Malviya N, Strunk A, Wright S, Alavi A, Alhusayen R, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022;86(5):1092\u2013101.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"796_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000503605","volume":"237","author":"AJ Hendricks","year":"2021","unstructured":"Hendricks AJ, Hsiao JL, Lowes MA, Shi VY. A comparison of international management guidelines for hidradenitis suppurativa. Dermatology. 2021;237(1):81\u201396.","journal-title":"Dermatology"},{"issue":"9","key":"796_CR15","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamadermatol.2014.691","volume":"150","author":"JS Kirby","year":"2014","unstructured":"Kirby JS, Miller JJ, Adams DR, Leslie D. Health care utilization patterns and costs for patients with hidradenitis suppurativa. JAMA Dermatol. 2014;150(9):937\u201344.","journal-title":"JAMA Dermatol"},{"issue":"5 Suppl 1","key":"796_CR16","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jaad.2015.07.052","volume":"73","author":"GB Jemec","year":"2015","unstructured":"Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73(5 Suppl 1):S4-7.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"796_CR17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/bjd.19626","volume":"184","author":"D Bouazzi","year":"2021","unstructured":"Bouazzi D, McPhie ML, Kj\u00e6rsgaard Andersen R, Alavi A, Jemec GBE. Hidradenitis suppurativa and perceived stigmatization in a diverse Canadian clinic population: a pilot study. Br J Dermatol. 2021;184(3):570\u20131.","journal-title":"Br J Dermatol"},{"issue":"6","key":"796_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000453355","volume":"232","author":"A Kouris","year":"2016","unstructured":"Kouris A, Platsidaki E, Christodoulou C, Efstathiou V, Dessinioti C, Tzanetakou V, et al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology. 2016;232(6):687\u201391.","journal-title":"Dermatology"},{"issue":"1","key":"796_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/bjd.17101","volume":"181","author":"T Tzellos","year":"2019","unstructured":"Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J. Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol. 2019;181(1):147\u201354.","journal-title":"Br J Dermatol"},{"issue":"5","key":"796_CR20","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.jaad.2020.07.115","volume":"84","author":"KR van Straalen","year":"2021","unstructured":"van Straalen KR, Prens LM, Hylkema TH, Janse IC, Dickinson J, Houwing R, et al. Impact of hidradenitis suppurativa on work productivity and associated risk factors. J Am Acad Dermatol. 2021;84(5):1401\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"796_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaad.2019.11.068","volume":"83","author":"KR Patel","year":"2020","unstructured":"Patel KR, Lee HH, Rastogi S, Vakharia PP, Hua T, Chhiba K, et al. Association between hidradenitis suppurativa, depression, anxiety, and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;83(3):737\u201344.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"796_CR22","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A, Neuren E, Cha D, Kirby JS, Ingram JR, Jemec GBE, et al. Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366\u201376.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"796_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030579","volume":"9","author":"J Marvel","year":"2019","unstructured":"Marvel J, Vlahiotis A, Sainski-Nguyen A, Willson T, Kimball A. Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data. BMJ Open. 2019;9(9): e030579.","journal-title":"BMJ Open"},{"issue":"5","key":"796_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"6","key":"796_CR25","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"796_CR26","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/MLR.0b013e31819432e5","volume":"47","author":"C van Walraven","year":"2009","unstructured":"van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47(6):626\u201333.","journal-title":"Med Care"},{"issue":"5","key":"796_CR27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ijwd.2019.06.026","volume":"5","author":"A Cartron","year":"2019","unstructured":"Cartron A, Driscoll MS. Comorbidities of hidradenitis suppurativa: a review of the literature. Int J Womens Dermatol. 2019;5(5):330\u20134.","journal-title":"Int J Womens Dermatol."},{"issue":"1062","key":"796_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/postgradmedj-2013-131994","volume":"90","author":"DN Dufour","year":"2014","unstructured":"Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J. 2014;90(1062):216\u201321 (quiz 20).","journal-title":"Postgrad Med J"},{"issue":"1","key":"796_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13555-020-00354-2","volume":"10","author":"T Tzellos","year":"2020","unstructured":"Tzellos T, Zouboulis CC. Review of comorbidities of hidradenitis suppurativa: implications for daily clinical practice. Dermatol Ther (Heidelb). 2020;10(1):63\u201371.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"4","key":"796_CR30","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/bjd.14976","volume":"176","author":"N Desai","year":"2017","unstructured":"Desai N, Shah P. High burden of hospital resource utilization in patients with hidradenitis suppurativa in England: a retrospective cohort study using hospital episode statistics. Br J Dermatol. 2017;176(4):1048\u201355.","journal-title":"Br J Dermatol"},{"issue":"4","key":"796_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s13555-018-0264-z","volume":"8","author":"AB Kimball","year":"2018","unstructured":"Kimball AB, Sundaram M, Gauthier G, Gu\u00e9rin A, Pivneva I, Singh R, et al. The comorbidity burden of hidradenitis suppurativa in the United States: a claims data analysis. Dermatol Ther (Heidelb). 2018;8(4):557\u201369.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"7","key":"796_CR32","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/jamadermatol.2019.0164","volume":"155","author":"S Reddy","year":"2019","unstructured":"Reddy S, Strunk A, Garg A. Comparative overall comorbidity burden among patients with hidradenitis suppurativa. JAMA Dermatol. 2019;155(7):797\u2013802.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"796_CR33","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1111\/bjd.16603","volume":"183","author":"\u0141 Matusiak","year":"2020","unstructured":"Matusiak \u0141. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol. 2020;183(6):e171\u20137.","journal-title":"Br J Dermatol"},{"issue":"12","key":"796_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11916-017-0647-3","volume":"21","author":"ZS Patel","year":"2017","unstructured":"Patel ZS, Hoffman LK, Buse DC, Grinberg AS, Afifi L, Cohen SR, et al. Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa [corrected]. Curr Pain Headache Rep. 2017;21(12):49.","journal-title":"Curr Pain Headache Rep"},{"issue":"2","key":"796_CR35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/bjd.17123","volume":"180","author":"A Pavon Blanco","year":"2019","unstructured":"Pavon Blanco A, Turner MA, Petrof G, Weinman J. To what extent do disease severity and illness perceptions explain depression, anxiety and quality of life in hidradenitis suppurativa? Br J Dermatol. 2019;180(2):338\u201345.","journal-title":"Br J Dermatol"},{"issue":"4","key":"796_CR36","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jamadermatol.2020.5435","volume":"157","author":"C Liy-Wong","year":"2021","unstructured":"Liy-Wong C, Kim M, Kirkorian AY, Eichenfield LF, Diaz LZ, Horev A, et al. Hidradenitis suppurativa in the pediatric population: an international, multicenter, retrospective, cross-sectional study of 481 pediatric patients. JAMA Dermatol. 2021;157(4):385\u201391.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"796_CR37","volume":"12","author":"SR Resnik","year":"2020","unstructured":"Resnik SR, Geisler EL, Reyes N, Lozano J, Ramirez-Caussade RA, Resnik B. Prevalence and risk factors for anemia in a population with hidradenitis suppurativa. Cureus. 2020;12(12): e12015.","journal-title":"Cureus."},{"issue":"6","key":"796_CR38","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/bjd.16931","volume":"179","author":"S Wertenteil","year":"2018","unstructured":"Wertenteil S, Strunk A, Garg A. Incidence of obstructive sleep apnoea in patients with hidradenitis suppurativa: a retrospective population-based cohort analysis. Br J Dermatol. 2018;179(6):1398\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"796_CR39","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jaad.2018.02.053","volume":"79","author":"A Garg","year":"2018","unstructured":"Garg A, Papagermanos V, Midura M, Strunk A, Merson J. Opioid, alcohol, and cannabis misuse among patients with hidradenitis suppurativa: a population-based analysis in the United States. J Am Acad Dermatol. 2018;79(3):495-500.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"796_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031810","volume":"7","author":"R Sabat","year":"2012","unstructured":"Sabat R, Chanwangpong A, Schneider-Burrus S, Metternich D, Kokolakis G, Kurek A, et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS ONE. 2012;7(2): e31810.","journal-title":"PLoS ONE"},{"issue":"2","key":"796_CR41","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jaad.2018.06.028","volume":"80","author":"A Rondags","year":"2019","unstructured":"Rondags A, van Straalen KR, Arends S, van der Zee HH, Prens EP, Spoorenberg A, et al. High prevalence of clinical spondyloarthritis features in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2019;80(2):551-4.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"796_CR42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14737167.2021.1895753","volume":"22","author":"K G\u00e1sp\u00e1r","year":"2022","unstructured":"G\u00e1sp\u00e1r K, Hunor Gergely L, Jenei B, Wikonk\u00e1l N, Kiny\u00f3 \u00c1, Szegedi A, et al. Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. Expert Rev Pharmacoecon Outcomes Res. 2022;22(3):399\u2013408.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"796_CR43","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jaad.2020.07.108","volume":"84","author":"LAV Orenstein","year":"2021","unstructured":"Orenstein LAV, Wright S, Strunk A, Garg A. Low prescription of tumor necrosis alpha inhibitors in hidradenitis suppurativa: a cross-sectional analysis. J Am Acad Dermatol. 2021;84(5):1399\u2013401.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"796_CR44","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431175","volume":"231","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GBE. Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231(2):184\u201390.","journal-title":"Dermatology"},{"issue":"1","key":"796_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/jdv.15233","volume":"33","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, Bechara FG, Dickinson-Blok JL, Gulliver W, Horv\u00e1th B, Hughes R, et al. Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization\u2014systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"796_CR46","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.jaip.2017.10.024","volume":"6","author":"AM Drucker","year":"2018","unstructured":"Drucker AM, Qureshi AA, Amand C, Villeneuve S, Gadkari A, Chao J, et al. Health care resource utilization and costs among adults with atopic dermatitis in the United States: a claims-based analysis. J Allergy Clin Immunol Pract. 2018;6(4):1342\u20138.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"796_CR47","doi-asserted-by":"publisher","unstructured":"Kim GE, Shlyankevich J,  Kimball AB  (2014) The validity of the diagnostic code for hidradenitis suppurativa in an\nelectronic database. Br J Dermatol 171(2):338\u201342. https:\/\/doi.org\/10.1111\/bjd.13041","DOI":"10.1111\/bjd.13041"}],"updated-by":[{"DOI":"10.1007\/s40257-025-00938-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00796-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-023-00796-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00796-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:03:39Z","timestamp":1747209819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-023-00796-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["796"],"URL":"https:\/\/doi.org\/10.1007\/s40257-023-00796-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40257-025-00938-8","asserted-by":"object"}]},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,28]]},"assertion":[{"value":"16 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-025-00938-8","URL":"https:\/\/doi.org\/10.1007\/s40257-025-00938-8","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Novartis Pharma AG, Basel, Switzerland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Amit Garg is an advisor for AbbVie, Aclaris Therapeutics, Anaptys Bio, Aristea Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, InflaRx, Insmed, Janssen, Novartis, Pfizer, Sonoma Biotherapeutics, UCB, Union Therapeutics, and Viela Biosciences, and receives honoraria. He also receives research grants from AbbVie, UCB and the National Psoriasis Foundation, and is co-copyright holder of the HS-IGA and HiSQOL instruments. Yvonne Geissb\u00fchler and Craig Richardson are full-time employees of Novartis Pharma AG, Basel, Switzerland, and Emma Houchen is a full-time employee of Novartis Pharmaceuticals, Dublin, Ireland. Nilesh Choudhary, Disha Arora, Varun Vellanki, Abhishek Srivastava, and Priyanka are full-time employees of Novartis Pharmaceuticals Corporation, Hyderabad, India. John Darcy II is a full-time employee of Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Alexa B. Kimball\u2019s institution received grants from Abbvie, Anapyts Bio, Aristea, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, Moonlake, Novartis, Pfizer, UCB, and Sonoma Bio, and fellowship funding from Abbvie and Janssen. Alexa B. Kimball  received consulting fees from Abbvie, Alumis, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, FIDE, Novartis, Moonlake, Janssen, Pfizer, Priovant, Sonoma Bio, Sanofi UCB, and Ventyx; serves on advisory boards for Target RWE; serves as an advisory council member to the NIH Director; and  serves on the board of directors of Almirall.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data collected for this study will be made available to others upon request. Proposals for data requests will be reviewed and considered on an individual basis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: All authors. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: All authors. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: EH. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}